The leading diagnostic service provider, Metropolis Healthcare, has launched hypersensitivity pneumonitis (HP) profile, a new series of test for timely diagnosis of the condition. The test helps in identifying the allergens that causes HP.
No significant treatment or cure has been identified or developed to cure HP which is a rare immune system disorder that affects the lungs due to sensitization towards inhaled organic antigens (like toxins or enzymes) or low molecular weight chemical compounds.
These substances trigger the immune system, causing short or long term inflammation especially in part of the lungs hindering its normal function as the walls of the air sacks get filled with white blood cells and in some conditions with fluid. If the condition is not diagnosed on time and goes untreated, the chronic inflammation can cause serious irreversible lung scarring which is also known as pulmonary fibrosis.
Pigeon droppings and pigeon pertaining dust is the most common form of allergen that causes this ailment in India.
HP profile antibody testing is one of the diagnostic criteria for the test. It includes IgG test for – Alternaria, cladosposirum, penicllium, pigeon droppings, aspergillus, Mucor, etc.
Some widely cited set of criteria that help diagnose HP includes checking for symptoms compatible with the condition, examining evidence of exposure to an appropriate antigen by either the history or antibody testing results, diagnosis of interstitial lung disease with bronchoalveolar lavage (BAL) and histopathologic features compatible with HP.
HP can be treated and reversed by diagnosing the condition at an early stage by avoiding exposure to environmental substances like dust or medicines such as corticosteroids that mitigate the risk of inflammation. Hence it is imperative to diagnose the disease at a nascent stage.
“With HP affecting a large number of people, it has become even more essential to prevent, check for, monitor and diagnose the condition in time. We at Metropolis Healthcare believe in identifying such conditions and creating awareness about the same among people as they go largely undetected.” said Dr Deepak Sanghavi, Head-Technical Operations, West SBU India, Metropolis Healthcare, in a statement.